Heart Disease Trial, Recruiting NCT06420505 Sponsor: Translumina GmbH Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06420505
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who are able to sign a consent form agreeing to take part
  • Men, or women who are not pregnant (women of childbearing age will be asked verbally about pregnancy status)
  • People who have presented with a heart condition involving blocked or narrowed arteries, either as an urgent event or an ongoing condition with chest pain or related symptoms, or with test results showing reduced blood flow to the heart
  • People who have a social security number
  • People whose treatment involved only the Vivo ISAR stent, whether one or more blood vessels were treated

Who may not be able to join:

  • People who are currently taking part in another clinical trial
  • People who had a procedure to open a blocked artery using a different stent (not the Vivo ISAR) within the last month
  • People who have planned non-emergency surgery scheduled within the next 6 months
  • People who are in severe heart failure or whose condition is medically unstable at the time of the trial
  • People with another medical condition where life expectancy is estimated to be less than 12 months
  • People who have had a stroke within the last 6 months
  • People who are legally considered vulnerable and are under guardianship or protected legal status

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thibault Lhermusier, Pr, University Hospital, Toulouse

Phone: 0623822906

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Translumina GmbH
Registry
ClinicalTrials.gov
Start date
29 November 2023
Est. completion
29 November 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

rate of target lesion failure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov